Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04791228
Recruitment Status : Not yet recruiting
First Posted : March 10, 2021
Last Update Posted : August 3, 2021
Sponsor:
Information provided by (Responsible Party):
AeRang Kim, Children's National Research Institute

Brief Summary:
This is a pilot study of LTLD with MR-HIFU hyperthermia followed by ablation in subjects with refractory/relapsed solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumors Soft Tissue Sarcoma Ewing Sarcoma Malignant Epithelial Neoplasm Rhabdomyosarcoma Wilms Tumor Hepatic Tumor Germ Cell Tumor Bone Metastases Device: Magnetic Resonance-Guided High Intensity Focused Ultrasound Drug: Lyso-thermosensitive Liposomal Doxorubicin Phase 2

Detailed Description:
LTLD is a heat-activated formulation of liposomal doxorubicin that releases the drug when exposed to hyperthermic conditions (40-45°C). This novel agent has been well tolerated in adults with similar toxicity profile to doxorubicin. MR-HIFU offers a non-invasive and non-ionizing ability to selectively heat large tissue volumes. Thus, MR-HIFU is a promising technology for triggering doxorubicin release from LTLD. LTLD has been evaluated with ultrasound-guided high intensity focused ultrasound and found to be safe and feasible. Building upon recent mathematical as well as pre-clinical work, we will use an approach that capitalizes on MR-HIFU features to optimize drug delivery to the targeted tumor. Our approach involves continuous maintenance of the target at mild hyperthermia with MR-HIFU following LTLD infusion. Following hyperthermia, we will deliver ablation therapy (>55°C) to targeted areas of tumor where feasible and safe. Addition of this ablation therapy after mild-hyperthermia-triggered drug delivery with LTLD has the potential to significantly potentiate chemotherapy with minimal additional adverse effects to improve local control and drug delivery without increasing toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Treatment of Relapsed or Refractory Solid Tumors
Estimated Study Start Date : October 1, 2021
Estimated Primary Completion Date : June 1, 2024
Estimated Study Completion Date : June 1, 2024


Arm Intervention/treatment
Experimental: All Patients
LTLD 50 mg/m2 will be administered intravenously over 30 minutes on day 1 of every 21-day cycle. MR-HIFU hyperthermia will follow infusion (+/- 30 minutes) for one hour to a target area with a target temperature of 40-45°C followed by ablation therapy (>55°C). The HIFU hyperthermia regimen will have a duration of at least 60 minutes and will then be followed by ablation therapy. Patients may receive up to a total of 6 cycles. Subsequent treatment cycles may treat alternative target lesions. Disease status will be evaluated using standard imaging techniques (CT/MR) post each cycle.
Device: Magnetic Resonance-Guided High Intensity Focused Ultrasound

Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.

Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy.

Other Name: MR-HIFU

Drug: Lyso-thermosensitive Liposomal Doxorubicin

LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.

If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence.

Other Names:
  • LTLD
  • ThermoDox




Primary Outcome Measures :
  1. Primary objective 1: Response of treated target lesion(s) assessed by CT or MRI [ Time Frame: At the end of every 21-day cycle ]
    The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) will be used

  2. Primary objective 2: The number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria of Adverse Events (CTCAE) v.5 [ Time Frame: Up to thirty days after last dose of protocol therapy ]
    CTCAE v.5 will be used


Other Outcome Measures:
  1. Exploratory objective 1: Response of non-target lesion(s) assessed by CT or MRI [ Time Frame: At the end of every 21-day cycle ]
    Lesions that are evaluable or measurable but not in the treated location(s) will be collected

  2. Exploratory objective 2: Participant reported target tumor pain intensity assessed using the Numerical Rating Scale-11 (NRS-11) [ Time Frame: At the end of every 21-day cycle ]
    The NRS-11 consists of a 11-point numeric scale to assess pain intensity from 0 (no pain) to 10 (worst pain)

  3. Exploratory objective 3: Participant reported impact of pain on daily activities assessed using the PROMIS Pain Interference Scale (PROMIS-PI) [ Time Frame: At the end of every 21-day cycle ]
    The PROMIS-PI consists of 8 questions on pain. Each question will be rated from 0 (never), 1 (almost never), 2 (sometimes), 3 (often), and 4 (almost always)

  4. Exploratory objective 4: Blood samples taken to see adaptive immune response and immune suppression [ Time Frame: At 1 day and 1 week after MR-HIFU treatment on first 21-day cycle ]
    To determine changes in pharmacodynamics of immune markers



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • AGE: ≥ 12 years of age.
  • DIAGNOSIS: Histologically confirmed malignant solid tumors
  • TUMOR LOCATION: Patient must have at least one tumor located in areas accessible to HIFU, which will be defined as the target lesion(s). Target lesions must be reachable within the normal safety margins of HIFU as specified in the instructions for use.
  • TARGET LESION(S): Radiographically measurable/evaluable solid tumor target lesion(s).
  • THERAPEUTIC OPTIONS:

    - Malignant Tumor: The patient's cancer must have relapsed after or failed to respond to frontline curative therapy and there must not be other potentially curative treatment options available.

  • PRIOR THERAPY:

    • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study.
    • No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry.
    • Myelosuppressive chemotherapy: The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks prior to study entry (6 weeks for prior nitrosoureas) Prior treatment with anthracyclines is allowed as long as total cumulative dose is ≤ 450 mg/m2.
    • Immunotherapy: The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 3 weeks prior to study entry.
    • Biologic (anti-cancer agent): The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry.
    • Radiation therapy: The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry.
    • Stem Cell Transplantation. At least 42 days post-autologous stem cell transplant or at least 90 post-allogeneic transplant and recovered from toxicities without evidence of graft versus host disease and on stable doses of immunosuppressive medications if required.
    • Growth Factors. The last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry.
  • CONCURRENT THERAPIES:

    - No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted.

  • PERFORMANCE STATUS:

    • Lansky/Karnofsky performance level ≥ 50% (See Appendix I).
    • Patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score.
  • HEMATOLOGIC FUNCTION:

    • Peripheral absolute neutrophil count (ANC) of ≥ 1000/µL.
    • Platelet count ≥ 75,000/µL (transfusion independent (no transfusion within at least 7 days prior to enrollment)).
  • HEPATIC FUNCTION:

    • Total bilirubin must be ≤ 1.5 times the upper limit of normal (ULN) for age and gender.
    • SGPT (ALT) must be ≤ 3.0 times the upper limit of normal for age.
  • RENAL FUNCTION: Serum creatinine ≤ ULN for age/sex OR a creatinine clearance ≥60 mL/min/1.73 m2.
  • CARDIAC FUNCTION: Adequate Cardiac Function with Ejection Fraction > 50% by echocardiogram.

Exclusion Criteria:

  • Clinically significant unrelated systemic illness, such as serious infections, hepatic, renal or other organ dysfunction, which in the judgment of the Principal or Associate Investigator would compromise the patient's ability to tolerate study interventions.
  • Patients who are pregnant or breast-feeding are not eligible for this study due to risks of fetal and teratogenic adverse events seen in animal/human studies with doxorubicin. Negative pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method beginning at the signing of informed consent and until at least 30 days after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or designated associate.
  • Implant or prosthesis within the path of the HIFU beam.
  • Target pathway <1 cm from nerve plexus, spinal canal, or bowel.
  • Target lesion in the skull.
  • Inability to undergo MRI and/or contraindication for MRI.
  • Inability to tolerate stationary position during HIFU.
  • Previous history of hypersensitivity to doxorubicin or its liposomal formulations.
  • Patients currently receiving other anticancer agents.
  • Patients currently receiving other investigational agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04791228


Contacts
Layout table for location contacts
Contact: General HIFU trials 202-476-6755 HIFUtrials@childrensnational.org

Sponsors and Collaborators
Children's National Research Institute
Investigators
Layout table for investigator information
Principal Investigator: AeRang Kim, MD, PhD Children's National Research Institute
Layout table for additonal information
Responsible Party: AeRang Kim, Oncologist, Children's National Research Institute
ClinicalTrials.gov Identifier: NCT04791228    
Other Study ID Numbers: HIFU Thermodox PII
First Posted: March 10, 2021    Key Record Dates
Last Update Posted: August 3, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by AeRang Kim, Children's National Research Institute:
Relapsed/refractory solid tumors
High Intensity Focused Ultrasound
Lyso-thermosensitive Liposomal Doxorubicin
ThermoDox
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhabdomyosarcoma
Neoplasms
Sarcoma
Sarcoma, Ewing
Wilms Tumor
Neoplasms, Glandular and Epithelial
Carcinoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Myosarcoma
Neoplasms, Muscle Tissue
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Complex and Mixed
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplastic Syndromes, Hereditary
Kidney Diseases
Urologic Diseases
Genetic Diseases, Inborn
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors